Rekah Pharmaceutical Industry Ltd Working Capital to Net Assets Ratio
Rekah Pharmaceutical Industry Ltd working capital to net assets ratio. Rekah Pharmaceutical Industry Ltd (REKA) has a Working Capital to Net Assets ratio of 50.7% as of June 2026. Working capital of ILA71.06 Million (current assets of ILA244.35 Million minus current liabilities of ILA173.29 Million) is measured against net assets of ILA140.18 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is Rekah Pharmaceutical Industry Ltd's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Rekah Pharmaceutical Industry Ltd (2012–2025)
Working capital to net assets ratio of Rekah Pharmaceutical Industry Ltd from 2012 to 2025. This chart shows how Rekah Pharmaceutical Industry Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 50.7%, reflecting working capital of ILA71.06 Million against net assets of ILA140.18 Million ILA. See Rekah Pharmaceutical Industry Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Rekah Pharmaceutical Industry Ltd Working Capital to Net Assets Ratio by Year (2012–2025)
Rekah Pharmaceutical Industry Ltd working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Rekah Pharmaceutical Industry Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Rekah Pharmaceutical Industry Ltd's balance sheet.
| Year | WC/NA Ratio | Working Capital (ILA) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 56.0% | ILA80.82 Million | ILA144.21 Million | ILA232.68 Million | ILA151.87 Million | ▲ +12.2 pp |
| 2024 | 43.8% | ILA71.01 Million | ILA161.98 Million | ILA229.05 Million | ILA158.04 Million | ▼ -25.3 pp |
| 2023 | 69.1% | ILA107.54 Million | ILA155.59 Million | ILA251.33 Million | ILA143.79 Million | ▲ +4.9 pp |
| 2022 | 64.2% | ILA104.11 Million | ILA162.08 Million | ILA243.14 Million | ILA139.03 Million | ▼ -6.9 pp |
| 2021 | 71.1% | ILA123.05 Million | ILA173.06 Million | ILA221.66 Million | ILA98.61 Million | ▼ -0.8 pp |
| 2020 | 71.9% | ILA119.09 Million | ILA165.59 Million | ILA227.35 Million | ILA108.26 Million | ▲ +12.0 pp |
| 2019 | 59.9% | ILA93.00 Million | ILA155.22 Million | ILA177.68 Million | ILA84.68 Million | ▼ -17.9 pp |
| 2018 | 77.9% | ILA117.30 Million | ILA150.66 Million | ILA197.15 Million | ILA79.85 Million | ▼ -1.3 pp |
| 2017 | 79.1% | ILA114.43 Million | ILA144.62 Million | ILA192.40 Million | ILA77.97 Million | ▼ -47.3 pp |
| 2016 | 126.4% | ILA133.85 Million | ILA105.86 Million | ILA226.99 Million | ILA93.14 Million | ▲ +14.8 pp |
| 2015 | 111.6% | ILA138.05 Million | ILA123.66 Million | ILA230.50 Million | ILA92.45 Million | ▼ -3.9 pp |
| 2014 | 115.5% | ILA89.03 Million | ILA77.06 Million | ILA220.72 Million | ILA131.69 Million | ▲ +87.9 pp |
| 2013 | 27.7% | ILA22.00 Million | ILA79.51 Million | ILA223.68 Million | ILA201.68 Million | ▲ +3.4 pp |
| 2012 | 24.2% | ILA17.25 Million | ILA71.17 Million | ILA213.94 Million | ILA196.69 Million | — |